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Abstract
Flavonolignans from milk thistle (Silybum marianum) have been investigated for their cellular
modulatory properties, including cancer chemoprevention and hepatoprotection, as an extract
(silymarin), as partially purified mixtures (silibinin and isosilibinin), and as pure compounds (a
series of seven isomers). One challenge with the use of these compounds in vivo is their relatively
short half-life due to conjugation, particularly glucuronidation. In an attempt to generate analogues
with improved in vivo properties, particularly reduced metabolic liability, a semi-synthetic series
was prepared in which the hydroxy groups of silybin B were alkylated. A total of five methylated
analogues of silybin B were synthesized using standard alkylation conditions (dimethyl sulfate and
potassium carbonate in acetone), purified using preparative HPLC, and elucidated via
spectroscopy and spectrometry. Of the five, one was monomethylated (3), one was dimethylated
(4), two were trimethylated (2 and 6), and one was tetramethylated (5). The relative potency of all
compounds was determined in a 72 hr growth-inhibition assay against a panel of three prostate
cancer cell lines (DU-145, PC-3, and LNCaP) and a human hepatoma cell line (Huh7.5.1) and
compared to natural silybin B. Compounds also were evaluated for inhibition of both cytochrome
P450 2C9 (CYP2C9) activity in human liver microsomes and hepatitis C virus infection in
Huh7.5.1 cells. The monomethyl and dimethyl analogues were shown to have enhanced activity in
terms of cytotoxicity, CYP2C9 inhibitory potency, and antiviral activity (up to 6-fold increased
potency) compared to the parent compound, silybin B. In total, these data suggested that
methylation of flavonolignans can increase bioactivity.
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1. Introduction
Our research team has been studying the chemopreventive properties of a series of
flavonolignans isolated from an extract (termed ‘silymarin’)1 of milk thistle [Silybum
marianum (L.) Gaertn. (Asteraceae)].2–8 In vitro and human tumor xenograft anticancer
activity of the commercial extracts, silymarin and silibinin, has been demonstrated in models
of prostate, colon, and breast cancer. The extracts, and a subset of pure compounds derived
therefrom, have been studied most extensively in prostate carcinoma cell lines, where they
exhibit antiproliferative and pro-apoptotic activity via inhibition of expression of cyclins and
cyclin-dependent kinases, induction of p21 and p27, degradation of androgen receptor, and
activation of caspase-3 and caspase-9.2–8 Studies on the natural products chemistry of these
compounds led to the gram-scale isolation of the flavonolignans,9 which consist of a series
of seven diastereo or constitutional isomers, and the isolation and identification of two new
minor analogs.10 Besides chemoprevention, some of these materials have been evaluated as
inhibitors of cytochrome P450 2C9 (CYP2C9)11 activity and activities associated with
hepatoprotection.12–15
A challenge of working with milk thistle products has been translating the results from in
vitro studies to the clinic, likely due to suboptimal pharmacokinetic characteristics of the
compounds.16 The pharmacokinetics of unconjugated and conjugated (sulfated and
glucuronidated) flavonolignans from milk thistle were examined after oral administration of
up to 700 mg/day silymarin, and 28% and 55% of the total silymarin compounds in plasma
were found as sulfate and glucuronide conjugates, respectively, after 1–3 hr.17 Even with
doses of 13 g/day with a silibinin derived product in clinical studies by Flaig et al.,18 a major
challenge to in vivo activity was extensive conjugation at phenolic positions. Conversely,
these same phenolic moieties may present opportunities for the semi-synthetic modification
of milk thistle compounds, if those that are or are not key for biological activity could be
identified.
Other research groups have probed the semisynthesis of analogues of silibinin19,20 (a 1:1
mixture of silybin A and silybin B)1 and/or 2,3-dehydrosilybin.21,22 The present
semisynthetic studies were designed with two central goals. The primary chemistry goal was
to determine which methylated analogues could be generated readily using a straightforward
alkylation procedure. For this, selectivity was not critical, as it was desirable to examine the
various permutations of single-, double-, triple-, and tetra-methylated silybin B analogues.
The primary pharmacology goal was to determine how these structural variations affected
the antiproliferative activity of silybin B (1). A secondary pharmacology goal was to
examine the compounds for inhibition of CYP2C9 activity and of antiviral activity against
hepatitis C virus (HCV). For the synthetic experiments, 1 was utilized as a representative
flavonolignan, since it is a major component of both silibinin and silymarin,2 there was an
ample supply of >98% pure material on the gram scale available, and it was the easiest of
the seven flavonolignans to purify.9 Compounds that were monomethylated or dimethylated
were more potent than 1, with the most potent being the dimethylated analogue (compound
4; approximately 6 times more active). These data suggested that alkylation of the phenolic
moieties of the flavonolignans presents a strategy for their continued exploration.
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2. Results and discussion
2.1 Synthesis and isolation
Silybin B (1) starting material was isolated in >98% purity from milk thistle extract
(silymarin) as described in detail previously.9 Methylated analogues of 1 were prepared in a
manner similar to that of Dzubak and colleagues; 22 however, those researchers used a
mixture of silybin A and silybin B (1) (often termed silibinin),1 and thus their analogues
were generated as diastereomeric mixtures.22 Briefly, dimethyl sulfate was added to a
solution of 1 and potassium carbonate in anhydrous acetone. The mixture was heated at
reflux for 30 min, cooled to room temperature, acidified with dilute hydrochloric acid, and
extracted with ethyl acetate. The organic extracts were combined and concentrated to
dryness under reduced pressure. The resulting oil was purified using RP-HPLC to yield five
major products (compounds 2–6; Fig. 1) in greater than 95% purity as measured by
analytical RP-HPLC (Fig. S1; the numbering of the compounds corresponds to their elution
order).
2.2 Structure elucidation
The structures of the five methylated analogues of silybin B (1) were elucidated using a suite
of NMR experiments in conjunction with HRMS data. Tables 1 and 2 summarize the 1H
and 13C NMR data, respectively, for compounds 2–6 in comparison to the well established
data for 1. The supplement includes the 1H and 13C NMR data as stack plots (Figs. S2 and
S3, respectively) and illustrates the ECD data (Fig. S4), which verified that all analogues
retained the configuration of 1.
Of the five compounds, one was monomethylated (3), one was dimethylated (4), two were
trimethylated (2 and 6), and one was tetramethylated (5). The signals for methoxy groups in
the 1H and 13C NMR spectra (i.e. δH 3.2–3.8 and δC 55–59, respectively) helped identify the
number of methyl groups incorporated in the structure of 1; the HRMS data served to verify
the number of additional methyl groups. For example, compound 2, which was the major
product of the reaction, was 5,7,4″-tri-O-methylsilybin B (2). Key HMBC signals that
established the positions of the methyl moieties included correlations from OCH3-5 to C-5,
from OCH3-7 to C-7, and from OCH3-4″ to C-4″ (Fig. 2). HRESIMS data confirmed the
addition of three methyl groups in the structure (m/z 547.1579 [M + Na]+, calcd for
C28H28O10Na, 547.1580). The other analogues displayed similar HMBC correlations,
thereby establishing the structures of 7-O-methylsilybin B (3), 7, 4″-di-O-methylsilybin B
(4), 5,7,4″,γ-tetra-O-methylsilybin B (5), and 7,4″,γ-tri-O-methylsilybin B (6). As with
compound 2, these structures were supported by HRMS data (see experimental).
2.3 Bioassay results
2.3.1 Antiproliferative assays—The potency of the analogues (2–6) was determined in
a 72 hr growth-inhibition assay relative to silybin B (1) and against a panel of three prostate
cancer cell lines (DU-145, PC-3, and LNCaP) and a human hepatoma cell line (Huh7.5.1;
Table 3). For inhibition of prostate cancer cells, the most potent analogue (~6-fold increased
potency) was compound 4, corresponding to methylation of the phenolic moieties at
positions 7 and 4″, yielding IC50 values that were ≤10 µM against two of the cell lines
(DU-145 and PC-3). The next most potent analogue, having a single methyl group at the 7
position (3), was approximately a factor of two less active than 4. However, all of the
compounds were equal to or slightly more potent (up to 6-fold increased potency) than the
parent (1; mean IC50 = 61.8 µM in DU-145 cells). Similarly, for inhibition of hepatoma cell
growth, all of the methylated compounds were more potent than the parent. In particular,
compounds 3 and 4 were over 5-fold more potent than the parent (1). In sum total, these
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cytotoxicity data, regardless of cell type, suggested that modifications at any of the phenolic
moieties could generate compounds that enhance the antiproliferative potency of silybin B
(1).
2.3.2 Inhibition of CYP2C9 activity—The inhibitory effects of four of the major
compounds found in silymarin (silybin A, silybin B (1), isosilybin A, and isosilybin B) on
the CYP2C9-mediated metabolism of (S)-warfarin were reported recently.11 Silybin B (1)
was the most potent of the four, with an IC50 value of 8.2 µM.11 Accordingly, the CYP2C9
inhibitory potencies of the methylated analogues (2–5) were compared (Fig. 3); compound 6
was not evaluated due to paucity of sample. With the exception of 5, all compounds
inhibited CYP2C9 activity in a concentration-dependent manner (1 vs. 10 µM). Compound 2
was less potent than 1 at 100 µM, whereas compounds 3 and 4, representing
monomethylation at the 7-OH and dimethylation at the 7- and 4″-OH moieties, respectively,
were more potent than 1, with activities below the limit of quantification when tested at 100
µM. These results suggested that despite increased cytotoxic potency, methylation of silybin
B may modulate the clearance of drugs metabolized by CYP2C9.
2.3.3. Inhibition of hepatitis C virus (HCV) infection—Figure 4 illustrates the
antiviral profile of compounds 2–5 against HCV infection of human hepatoma Huh7.5.1
cells; compound 6 was not evaluated due to paucity of sample. Previous studies indicated
that the IC50 value for inhibition of HCV infection by silybin B (1) was approximately 40 to
80 µM.13 The tested analogues of 1 inhibited HCV infection at lower concentrations, and the
dimethyl analogue 4 was the most potent. These data indicated that methylated silybin B
analogues were more active than 1 as antivirals in the following order: dimethyl (4) >
monomethyl (3) > tetramethyl (5) > trimethyl (2) > 1. It was intriguing that both the
cytotoxicity and antiviral activities were enhanced by methylation, even though the antiviral
testing was conducted at non-toxic concentrations of the analogues.
3. Conclusion
In summary, a series of methylated analogues of silybin B (1) were synthesized; some of
these analogues have been reported previously, albeit in the context of diastereomeric
mixtures with silybin A analogues.22 In the case of the dimethyl (4) and monomethyl (3)
analogues, and irrespective of the biological assay, the bioactivity increased relative to 1 in
terms of growth inhibition of prostate and liver cancer cells, inhibition of CYP2C9 activity,
and antiviral activity against HCV. These data suggest the feasibility of retaining and even
enhancing the bioactivity of silymarin-derived compounds, and provides a rationale for
methylating other isomers to test in anticancer, antiviral, metabolic, and pharmacologic
assays. Ultimately, such studies could provide valuable structure-activity relationships for
delineating the mechanisms of action of flavonolignans, which could aid in understanding
how these compounds act in many inflammatory disease states.
4. Experimental
4.1 General experimental methods
Optical rotation, UV, and IR data were acquired on a Rudolph Research Autopol® III
polarimeter, a Varian Cary 3 UV-Vis spectrophotometer, and a Nicolet Avatar 360 FT-IR,
respectively. Circular dichroism spectra were obtained from an Aviv Stopped Flow Model
202 circular dichroism spectrometer. All NMR experiments were acquired on a Varian
Unity INOVA-500 instrument using a 5 mm broad-band inverse probe with z?gradient using
DMSO-d6. LRESIMS data were acquired using an API 150EX mass spectrometer. HRMS
data were acquired on an Applied Biosystems 4700 TOF/TOF instrument operating in
Sy-Cordero et al. Page 4













reflectron mode using 2,5 dihydroxybenzoic acid as the matrix. For those data, spectra were
the average of 500–1000 laser shots, and the mass values were the mean of five independent
measurements. Some HRMS data were also acquired on a Thermo LTQ Orbitrap XL mass
spectrometer equipped with an ESI source. Preparative HPLC was carried out on a Varian
Prostar HPLC system equipped with Prostar 210 pumps and a 335 photodiode array detector
(PDA), with data collected and analyzed using Galaxie Chromatography Data System
software (version 1.9), using an ODS-A column (250 × 20 mm, i.d., 5 µm; YMC,
Wilmington, NC) at a flow rate of 7 mL/min. This same system and software were used for
analytical HPLC via an ODS-A column (150 × 4.6 mm, i.d., 5 µm) at a flow rate of 1 mL/
min.
4.2 Synthesis and purification
Silybin B (1) was isolated in >98% purity from milk thistle extract (silymarin) as described
in detail previously.9 Methylated analogs of 1 were prepared in a manner analogous to that
of Dzubak and colleagues.22 Dimethyl sulfate (0.20 g, 1.55 mmol) was added to a solution
of 1 (0.15 g, 0.31 mmol) and K2CO3 (0.35 g, 2.48 mmol) in anhydrous acetone (5 mL). The
suspension was allowed to stir at reflux for 30 min and was then cooled to room
temperature. The suspension was diluted with 1 N HCl (5 mL) and extracted with EtOAc (3
× 5 mL). The organic extracts were combined, dried (MgSO4), and concentrated under
reduced pressure to provide a brown oil (150 mg) as a mixture of methylated analogs.
4.2.1 Purification—The reaction product (150 mg) was dissolved in DMSO (500 µL) and
purified via two separate rounds (~75 mg/round) of RP-HPLC using a gradient that initiated
with 60:40 MeOH:H2O and increased linearly to 70:30 MeOH:H2O over 60 min, where it
was held isocratic for another 40 min, to yield compounds 2 (25.1 mg; 16.7%), 3 (10.6 mg;
7.1%), 4 (14.5 mg; 9.7%), 5 (12.0 mg; 8.0%), and 6 (2.7 mg; 1.8%).
4.2.1.1 Silybin B (1): The physical properties of 1 were described in detail previously.23,24
4.2.1.2 5,7,4″-Tri-O-methylsilybin B (2): white solid (25.1 mg, yield 16.7% w/w); tR 7.65
min in 60:40→100:0 MeOH-H2O over 15 min with the ODS A column; [α]D25 –10.67 (c
0.6, MeCN); UV (MeOH) γmax (log ε) 283 (5.25), 205 (5.88) nm; CD (MeOH) λext (Δε)
333 (+3.3), 293 (−19.7), 233 (+21.6) nm; IR (KBr) νmax 3438, 2934, 1672, 1606, 1571,
1508, 1422, 1257, 1214, 1106, 1021, 985, 812 cm−1; 1H and 13C NMR data, see Tables 1
and 2; HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10;
H-8 → C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′,
4′, 5′; H-α → C-β, γ, 4′, 1″; H-β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ →
C-1″, 3″, 4″, 6″; H-5″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″→
C-3″; OCH3-5 → C-5; OCH3-7 → C-7; OCH3-4″ → C-4″; HRESIMS m/z 547.1579 [M +
Na]+ (calcd for C28H28O10Na, 547.1580).
4.2.1.3 7-O-Methylsilybin B (3): white solid (10.6 mg, yield 7.1% w/w); tR 7.88 min in
60:40→100:0 MeOH-H2O over 15 min with the ODS A column; [α]D25 +2.67 (c 0.5,
MeOH); UV (MeOH) γmax (log ε) 287 (5.28), 204 (5.93) nm; CD (MeOH) λext (Δε) 333
(+3.7), 295 (−15.5), 234 (+12.4) nm; IR (KBr) νmax 3400, 2936, 1668, 1606, 1571, 1508,
1422, 1258, 1214, 1105, 1021, 986, 813 cm−1; 1H and 13C NMR data, see Tables 1 and 2;
HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10; H-8
→ C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′,
5′; H-α → C-β, γ, 4′, 1″; H-β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″,
3″, 4″, 6″; H-5″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″→ C-3″;
OCH3-7 → C-7; HRESIMS m/z 519.1271 [M + Na]+ (calcd for C26H24O10Na, 519.1267).
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4.2.1.4 7,4″-Di-O-methylsilybin B (4): white solid (14.5 mg, yield 9.7% w/w); tR 9.17 min
in 60:40→100:0 MeOH-H2O over 15 min with the ODS A column; [α]D25 +8.77 (c 0.7,
MeOH); UV (MeOH) γmax (log ε) 286 (5.26), 205 (5.93) nm; CD (MeOH) λext (Δε) 335
(+5.1), 294 (−21.8), 233 (+17.7) nm; IR (KBr) νmax 3432, 2937, 1670, 1606, 1572, 1508,
1422, 1258, 1214, 1105, 1021, 986, 811 cm−1; 1H and 13C NMR data, see Tables 1 and 2;
HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10; H-8
→ C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′,
5′; H-α → C-β, γ, 4′, 1″; H-β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″,
3″, 4″, 6″; H-5″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″→ C-3″;
OCH3-7 → C-7; OCH3-4″ → C-4″; HRESIMS m/z 533.1429 [M + Na]+ (calcd for
C27H26O10Na, 533.1424).
4.2.1.5 5,7,4″,γ-Tetra-O-methylsilybin B (5): white solid (12.0 mg, yield 8.0% w/w); tR
9.91 min in 60:40→100:0 MeOH-H2O over 15 min with the ODS A column; [α]D25 –6.18
(c 0.1, MeOH); UV (MeOH) γmax (log ε) 285 (5.26), 205 (5.91) nm; CD (MeOH) λext (Δε)
334 (+3.1), 294 (−16.2), 233 (+15.5) nm; IR (KBr) νmax 3424, 2936, 1670, 1606, 1571,
1508, 1422, 1257, 1214, 1106, 986, 812 cm−1; 1H and 13C NMR data, see Tables 1 and 2;
HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10; H-8
→ C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′,
5′; H-α → C-β, γ, 4′, 1″; H-β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″,
3″, 4″, 6″; H-5″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″→ C-3″;
OCH3-5 → C-5; OCH3-7 → C-7; OCH3-4″ → C-4″; OCH3-γ → C-γ; HRESIMS m/z
561.1746 [M + Na]+ (calcd for C29H30O10Na, 561.1737).
4.2.1.6 7,4″,γ-Tri-O-methylsilybin B (6): white solid (2.7 mg, yield 1.8% w/w); tR 11.03
min in 60:40→100:0 MeOH-H2O over 15 min with the ODS A column; [α]D25 +9.0 (c
0.05, MeOH); UV (MeOH) γmax (log ε) 286 (5.13), 205 (5.86) nm; CD (MeOH) λext (Δε)
335 (+4.0), 294 (−19.7), 232 (+17.4) nm; IR (KBr) νmax 3400, 2935, 1670, 1606, 1572,
1508, 1423, 1258, 1215, 1107, 1023, 951, 815 cm−1; 1H and 13C NMR data, see Tables 1
and 2; HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10;
H-8 → C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′,
4′, 5′; H-α → C-β, γ, 4′, 1″; H-β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ →
C-1″, 3″, 4″, 6″; H-5″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″→
C-3″; OCH3-7 → C-7; OCH3-4″ → C-4″; OCH3-γ → C-γ; HRESIMS m/z 525.1740 [M
+ H]+ (calcd for C28H29O10, 525.1755).
4.3 Biological Assays
4.3.1 Antiproliferative assay—All compounds were tested for antiproliferative/
cytotoxic activity against a panel of prostate cancer cell lines in culture using modifications
of a published procedure2 that have been described in detail.10 The prostate cancer cell lines
were obtained from the American Type Culture Collection (Manassas, VA): DU145
(HTB-81, an androgen-independent line derived from a central nervous system metastasis of
prostate adenocarcinoma), PC-3 (CRL-1435, an androgen-independent line derived from a
bone metastasis of prostate adenocarcinoma), and LNCaP (CRL-1740, an androgen-
dependent line derived from a lymph node metastasis of prostate adenocarcinoma). All cell
lines were cultured and maintained as described previously,2 with the recently noted
modification for LNCaP.10 We also tested the antiproliferative/cytotoxic activity of
compounds against a liver cancer cell line, Huh7.5.1.25 Briefly, 10,000 cells per well were
plated in 96-well plates, and following overnight incubation, were incubated with increasing
concentrations of compounds. Seventy-two hours later, cell viability was measured using the
ATPlite kit, as described previously,13 and an IC50 was calculated by linear regression using
GraphPad Prism.
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4.3.2 Inhibition of CYP2C9 activity—Silybin B (1) and methylated analogues (2–5)
were evaluated as inhibitors of CYP2C9 activity using (S)-warfarin and pooled human liver
microsomes (HLM) as described previously.11 Incubation mixtures consisted of HLM (0.1
mg/mL microsomal protein), (S)-warfarin (4 µM), silybin B or methylated analogue (1, 10,
or 100 µM), and potassium phosphate buffer (100 mM, pH 7.4). The CYP2C9 inhibitor
sulfaphenazole (1 µM) was used as a positive control. Control incubation mixtures contained
0.75% MeOH (v/v) in place of silybin B/methylated analogue or sulfaphenazole. Incubation
mixtures were analyzed for 7-hydroxywarfarin by HPLC/MS-MS as described previously.11
All statistical analyses for this assay were conducted using SigmaStat (version 3.5; Systat
Software, Inc., San Jose, CA). Data are presented as means ± SDs of triplicate incubations
unless indicated otherwise. Concentration-dependent inhibition of silybin B and methylated
analogs and comparisons between silybin B and methylated analogs were evaluated by two-
way analysis of variance (ANOVA); post hoc comparisons were made using Tukey’s test
when an overall difference resulted (p < 0.05).
4.3.3 Antiviral assays—The antiviral activity of 1–5 was evaluated by choosing two
concentrations that were non-toxic to cells. For this, 150,000 cells were plated in 12-well
plates, and the next day, cells were infected with JFH-1, a HCV that grows well in Huh7.5.1
cells, at a multiplicity of infection of 0.05 focus forming units per cell. Five hours post-
infection, virus inocula were removed and replaced with fresh medium containing
compounds. Protein lysates were harvested 72 hours later, and HCV proteins were detected
by Western blot analyses as described previously.13
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Structures of silybin B (1) and the methylated analogues 2–6.
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Key HMBC correlations for the major product of the reaction, 5,7,4″-tri-O-methylsilybin B
(2). The other analogues displayed similar data, depending on the number of methyl groups
incorporated.
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Effects of silybin B (1) and methylated analogues (2–5) on CYP2C9-mediated (S)-warfarin
7-hydroxylation in human liver microsomes (HLM). Incubation mixtures consisted of HLM
(0.1 mg/mL), (S)-warfarin (4 μM), silybin B or methylated analogue (1, 10, or 100 μM;
open, solid, and hatched bars, respectively) and potassium phosphate buffer (100 mM, pH
7.4). Reactions were initiated by the addition of NADPH (1 mM) and were terminated after
30 min with ice-cold MeOH (2 volumes). Activity in the presence of vehicle control (0.75%
MeOH, v/v) was 4.3 ± 0.26 pmol/min/mg microsomal protein. Bars and error bars denote
means and SDs, respectively, of triplicate incubations. BLQ, below limit of quantification.
*p < 0.05, 1 versus 10 μM; #p < 0.05, 10 versus 100 μM; †p < 0.05 versus silybin B at 100
μM (two-way ANOVA followed by Tukey’s test).
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Methylated analogues (2–5) were more potent than silybin B (1) in blocking HCV infection.
Human hepatoma Huh7.5.1 cells were infected with HCV in the presence of increasing
concentrations of analogues for 72 hours before cytoplasmic proteins were extracted and
HCV NS5A and core proteins detected by Western blot. Detection of cellular actin protein
served as a loading control. The concentrations selected for testing were nontoxic:
compound 2: 1.9, 9.4, 18.9 μM; compound 3: 2.0, 10.1 μM; compound 4: 1.9, 9.7 μM;
compound 5: 1.8, 9.2 μM. D refers to the DMSO solvent control.
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Table 3
Antiproliferative activity of silybin B (1) and analogues 2–6 against a panel of cell lines in culture.
Compound Mean IC50Values and Standard Deviations (µM)
DU-145 PC-3 LNCaP Huh7.5.1
1 61.8±3.3 60.5±4.3 69.6±3.8 56.2±2.8a
2 46.9±3.7 36.3±3.7 40.7±3.9 25.5±1.8
3 19.3±3.4 16.9±3.6 20.1±3.7 13.3±1.8
4 10.0±3.7 8.1±3.5 11.3±4.8 13.5±1.8
5 24.0±4.3a 14.4±4.4 30.1±3.7 15.6±1.8
6 16.8±3.9 21.9±4.1 19.8±4.8 Ntb
a
The IC50 values and standard deviations for these points were estimated based on visual inspection of sigmoidal dose response curves.
b
Not tested.
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